AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02788747 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection of placebo administered once daily for 28 consecutive days
Study NCT02054026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reducing the Risk
Study NCT03659019 — intervention group
Intervention type: OTHER
Intervention: Quality of life questionnaires
Description: During 10 years, the study will be conduct to obtain the quality of life evolution and medical complications in patients candidates but not implanted, and in patients candidates then implanted with the phrenic nerve stimulator.
Study NCT01967550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diclofenac diethylamine, DDEA 2.32% gel
Study NCT00085735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT00085735 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV
Study NCT02969148 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic bursectomy and D2 lymphadenectomy
Description: The anterior lobe of transverse mesocolon and capsula pancreatis will be dissected with the D2 lymphadenectomy according to the guidelines of National Comprehensive Cancer Network(NCCN) by laparoscopy，this is Laparoscopic bursectomy and D2 lymphadenectomy.
Study NCT02969148 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic D2 lymphadenectomy
Description: D2 lymphadenectomy is carried out according to the guidelines of National Comprehensive Cancer Network(NCCN).
Study NCT03078140 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Triferdine
Description: Triferdine 1 tablet daily Start from 14 weeks of gestation until delivery
Study NCT03078140 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Triferdine/Ferli-6
Description: For the participants assigned to this group, urine iodine level will be checked first.~For participants with normal urine iodine level, Ferli-6 1 tab daily will be given.~For those with low urine iodine level, Triferdine 1 tab daily will be given. Medication will be started from 14 weeks of gestation until delivery.
Study NCT03514810 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Combined Sertraline & Ketoprofen
Description: The first group of patients has administered sertralin (50mg)+placebo. The second group has administered sertralin (50mg)+ketoprofen (100mg) (Sertraline \& Ketoprofen) daily.
Study NCT03514810 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Combined Sertraline & Ketoprofen
Description: The first group of patients has administered sertralin (50mg)+placebo. The second group has administered sertralin (50mg)+ketoprofen (100mg) (Sertraline \& Ketoprofen) daily.
Study NCT03514810 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interleukins in MDD after treatment
Description: Some interleukine levels were estimated in the first group of patients (administered sertralin,50mg+ketoprofen,100mg) and compared with their level in the second group (administered sertralin (50mg)+placebo).
Study NCT03514810 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Interleukins in MDD after treatment
Description: Some interleukine levels were estimated in the first group of patients (administered sertralin,50mg+ketoprofen,100mg) and compared with their level in the second group (administered sertralin (50mg)+placebo).
Study NCT03966339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth hormone
Description: GH has been considered as a cogonadotropin, which plays an important role in the synthesis of ovarian steroid hormone and follicular development as a paracrine hormone.GH can regulate the growth hormone receptor and strengthen the function of mitochondria to improve the quality of the female oocyte.
Study NCT02206971 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: urine analyses feedback
Description: biomarker feedback report regarding the urine sample analyzed for the tobacco chemicals, cotinine, nicotine and NNAL
Study NCT01701232 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Patients will receive rituximab at a dose of 375 mg/m2 intravenously once a week for 4 weeks (on day 1,8,15,22)
Study NCT01701232 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: Patients will receive rituximab at a dose of 375 mg/m2 intravenously once a week for 4 weeks (on day 1,8,15,22)
Study NCT02870478 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine
Description: Dosing frequency comparison, using atropine sulfate 1% solution diluted to 0.01% and 0.05% by Leiter's Compounding Pharmacy
Study NCT01967550 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02247323 — intervention group
Intervention type: OTHER
Intervention: Risk of malignancy index
Description: Calculation of RMI before sugery.
Study NCT01223703 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: n-3 PUFAs
Description: 1.0 g gelatin capsules containing 850 to 882 mg of EPA and DHA ethyl esters in the average ratio EPA/DHA of 0.9:1.5 The treatment dose was five capsules daily for the first month followed by two capsules daily for the rest of the study.
Study NCT01223703 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1.0 g gelatin capsules containing olive oil. The treatment dose was five capsules daily for the first month followed by two capsules daily for the rest of the study
Study NCT04091633 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: WHO School Mental Health Program
Description: World Health Organization (WHO) School Mental Health Program (SMHP) is a manual based multi-component, multi-tiered and evidence-informed intervention for common mental health problems in school going children. SMHP is designed to be introduced into the normal classroom and school setting by trained teachers. The intervention has a universal component which takes a whole school approach that aims to promote mental health among all school children. It includes basic counseling skills for teachers, core values of mental health promoting schools and other health promoting efforts that impact upon mental health and can be administered to all students in school and classroom settings. The manual also contains targeted intervention strategies on anxiety, separation anxiety/ school refusal, post-trauma, depression, suicide, ADHD, autism, psychosis, conduct problems and substance use problems that can be implemented by teachers in classroom settings.
Study NCT04091633 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced School Mental Health Program (eSMHP)
Description: Informed by the results of pilot implementation, a number of content and delivery adaptations have been made to the School Mental Health Program (SMHP) to address the implementation challenges to scale-up of program in Pakistan. The adapted version of the intervention is called Enhanced School Mental Health Program (eSMHP). Enhancements to conventional SMHP have occurred at two levels: A) Content enhancements, such as a collaborative care model for engaging parents/primary caregivers, strategies for teacher's well-being, and adaptation and operationalization of particular clinical intervention strategies and B) Technological enhancements which include adaptation of the training manual for delivery using an online training platform, and a 'Chat-bot' to aid the implementation of intervention strategies in classroom settings.
Study NCT03740971 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning treatment
Description: Remote Ischemic Conditioning is given twice a day with 200mmHg pressure.
Study NCT03740971 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guideline-based therapy
Description: Guideline-based therapy
Study NCT01783327 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teens-Connect
Description: Teens-Connect combines Managing Diabetes and TEENCOPE. Managing Diabetes consists of 5 sessions on age-appropriate, educational content related to diabetes problem-solving and self-efficacy to improve self-management. TEENCOPE consists of 5 sessions designed to increase youth's sense of competence and mastery by retraining inappropriate or non-constructive coping styles and forming more positive styles and patterns of behavior. The program is highly interactive and youth can talk with each other on an online moderated discussion board. Youth will be asked to use the website at least twice per week for 4 weeks.
Study NCT01783327 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Planet D
Description: Planet D provides age-appropriate diabetes education on a variety of topics and social networking discussion boards on diabetes, food and exercise, personal interests, and diabetes camp. Planet D addresses emotions and self-management through education and social networking. Youth who register can also create a profile, upload and share pictures, identify favorite news and blog feeds as well as provide comments or tags to other members. Planet D has been online since 2007 and contains numerous diabetes-related articles geared toward youth as well as a secure message board. Youth will be asked to interact with the website twice a week for 4 weeks.
Study NCT04145011 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cooled Radiofrequency
Description: Delivery of energy to ablate sensory nerves via cooled radiofrequency probe (18g, 4mm active tip)
Study NCT04145011 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Radiofrequency
Description: Delivery of energy to ablate sensory nerves via non-cooled standard radiofrequency probe (22g, curved 10mm active tip)
Study NCT01883635 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Survivor-only progressive walking and resistance exercise
Description: Daily, home-based, tailored exercise program delivered over the course of 6 weeks to the survivor only
Study NCT01883635 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dyadic progressive walking and resistance exercise
Description: Daily, home-based, tailored exercise program delivered over the course of 6 weeks to the survivor and caregiver as a dyad
Study NCT02072811 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: DAC
Description: * DNR 60 mg/m2 0,5h infusion iv on 1-3 days~* 2-CdA 5 mg/m2 2h. infusion iv on 1-5 days~* Ara-C 200 mg/m2 12h infusion iv 2h after end of infusion with 2CdA on 1-7 days
Study NCT02072811 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: CLAG
Description: * G-CSF 30MU sc, on 0-5 days~* Mitoxantrone 10mg/m2 30 min infusion iv, on 1-3 days~* Cladribine 5mg/m2 in 2h infusion iv, on 1-5 days~* Ara-C 2000mg/m2 4h infusion iv, infusion start after 2h of Cladribine infusion end, on 1-5 day
Study NCT02072811 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Consolidation, I HAM cycle
Description: * Ara-C 3g/m2; 3h infusion iv every 12h on 1,2,3 days~* Mitoxantrone 10mg/m2; 0,5h infusion iv on 3,4,5 days
Study NCT02072811 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: II Consolidation HiDAraC
Description: • Ara-C 3g/m2 every 12h; 3h infusion iv on 1,3,5 days (+ mobilization of CD34+)
Study NCT02072811 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Consolidation, III HiDAraC cycle
Description: * Ara-C 3g/m2 every 12h; 3h infusion iv on 1,3,5 days~* 2-CdA 5 mg/m2 2h infusion iv on 1,3,5 days, 2h before Ara-C
Study NCT06454253 — intervention group
Intervention type: DEVICE
Intervention: Da Vinci Robot Surgical System
Description: Performing surgery on right colon cancer patients using the da Vinci robotic surgical system or laparoscopic surgical system
Study NCT03826550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Sodium Gel
Description: Twice daily for 60 days. Each patient is expected to receive 120 doses
Study NCT03826550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solaraze 3% Topical Gel
Description: Twice daily for 60 days. Each patient is expected to receive 120 doses
Study NCT03826550 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twice daily for 60 days. Each patient is expected to receive 120 doses
Study NCT01383837 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STYLEnS
Description: Multifamily group HIV/STI Prevention Intervention or Single Family Dyad (youth and a parent)
Study NCT01383837 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Promotion
Description: Health Promotion Intervention
Study NCT01086800 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Healthy Lifestyles and Sleep Education plus PAP
Description: Participants randomized to this arm will be educated on PAP and then use PAP for 3 months. They will also receive optimized medical preventive therapy according to current American Heart Association guidelines for prevention of CVD and sleep guidelines.
Study NCT02870478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine
Description: Dosing frequency comparison, using atropine sulfate 1% solution diluted to 0.01% and 0.05% by Leiter's Compounding Pharmacy
Study NCT03458013 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation
Description: Guided using an mp3 player and noise cancelling headphones, participants will be led through a series of mindfulness meditations lasting approximately 20 minutes each.
Study NCT01086800 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Healthy Lifestyles and Sleep Education plus Supplemental Oxygen
Description: Participants randomized to this arm will be educated on nocturnal supplemental oxygen and then use oxygen for 3 months. They also will receive optimized medical preventive therapy according to current American Heart Association guidelines for prevention of CVD and sleep guidelines.
Study NCT01086800 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Healthy Lifestyles and Sleep Education
Description: Participants randomized to this arm will receive optimized medical preventive therapy according to current American Heart Association guidelines for prevention of CVD and sleep guidelines.
Study NCT00717938 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: cisplatinum or carboplatin and e.g.etoposide.
Description: Standard chemotherapy treatment for patients with small cell lung cancer. Chemotherapy regimen contains a platinum drug and a topoisomerase inhibitor. Numbers of cycles 4-6 according to local variants. Used drugs=cisplatinum or carboplatin and e.g.etoposide. Treatment will be given every three weeks for 4-6 cycles according to local variants.
Study NCT00717938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatinum or carboplatin and e.g.etoposide+enoxaparin
Description: Standard chemotherapy treatment for patients with small cell lung cancer. Chemotherapy regimen contains a platinum drug and a topoisomerase inhibitor. Numbers of cycles 4-6 according to local variants. In addition to this, subjects will receive daily subcutaneous injections of enoxaparin during chemotherapy treatment.
Study NCT02715037 — intervention group
Intervention type: OTHER
Intervention: Throat swabbing
Study NCT02890810 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real Acupuncture with Electrical Stimulation
Description: Acupuncture is a therapy commonly used in East Asian countries, where the practitioner insert thin needles at specific body sites in order to relieve pain and illnesses. Recent studies found low frequency electricity applied through acupuncture needles can lead to profound pain relief by increasing endorphin levels in the central nervous system. Electroacupuncture will thus be used as the active intervention to treat chronic low back pain in this clinical study.
Study NCT02890810 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Simulated Acupuncture with Electrical Stimulation
Description: This intervention serves as the placebo control of the active intervention. Sterile acupuncture needles and the ITO electrical stimulators will be used in this intervention. But special care will be taken to have this intervention mimic the real treatment yet remaining as physiologically inert as possible.
Study NCT01972555 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally invasive aortic valve replacement
Study NCT01972555 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional aortic valve replacement
Study NCT04802993 — intervention group
Intervention type: OTHER
Intervention: Resection rates
Description: All groups are divided into one high- and one low resection rate group depending on percentage of patients with pancreatic ductal adenocarcinoma resected per county and year (first three groups) and resection rate of pancreaticoduodenectomy per 100 000 inhabitants per county (last three groups)
Study NCT02911922 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endorectal Balloon
Description: Endorectal balloon (ERB): Immobilization device manually placed into the rectum prior to radiation treatment planning CT and daily treatment delivery, to immobilize the prostate and reduce prostate motion.~Patients on each arm will receive 5 fractions of radiation, 7.25Gy per fraction, delivered 2-3 times a week (every other day excluding weekends), to total dose of 36.25 Gy. The total duration of treatment will be no shorter than 10 days.
Study NCT02911922 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rectal Spacer
Description: Rectal spacer (RS): Biodegradable gel that is transperineally injected between the rectum and prostate under transrectal ultrasound guidance, to increase physical distance and thereby reduce radiation dose to the anterior rectal wall. The spacer begins to biodegrade in 2-3 months, and is fully absorbed within 6 months.~Patients on each arm will receive 5 fractions of radiation, 7.25Gy per fraction, delivered 2-3 times a week (every other day excluding weekends), to total dose of 36.25 Gy. The total duration of treatment will be no shorter than 10 days.
Study NCT02911922 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Patients on each arm will receive 5 fractions of radiation, 7.25Gy per fraction, delivered 2-3 times a week (every other day excluding weekends), to total dose of 36.25 Gy. The total duration of treatment will be no shorter than 10 days.
Study NCT03033355 — intervention group
Intervention type: DRUG
Intervention: Intradetrusor injection of Botulinum Toxin-A
Description: Using cystoscopy, Botulinum Toxin-A is injected into the bladder.
Study NCT03739632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypidone Hydrochloride tablets
Description: Hypidone Hydrochloride tablets will be given orally, twice daily, for 6 weeks
Study NCT03739632 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets will be given orally, twice daily, for 6 weeks
Study NCT02195388 — intervention group
Intervention type: OTHER
Intervention: comprehensive cardiac rehabilitation
Description: Standard program of comprehensive cardiac rehabilitation CR with physical activity, behavioral intervention, risk factor modification and intervention.
Study NCT00993928 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based sleep intervention
Description: Participants will be asked to practice behaviors consistent with the stimulus control sheet and to read the sleep hygiene booklet.
Study NCT00993928 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home-based sleep intervention
Description: Participants will be asked to practice behaviors consistent with the stimulus control sheet and to read the sleep hygiene booklet.
Study NCT01359475 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acetal crown, LD Caulk ltd, USA
Description: Experimental trial of preformed acetal crowns for primary molars
Study NCT02774837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil
Description: Tenofovir disoproxil 300mg once daily for 96 weeks
Study NCT02774837 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil
Description: Tenofovir disoproxil 300mg once daily for 96 weeks
Study NCT02774837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telbivudine
Description: Telbivudine oral tablets 600mg once daily for 96 weeks
Study NCT04627272 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AutoDX-DR
Description: AutoDx-DR provides basic image interpretation for the detection of DR and diabetic macular edema (DME) and a Refer or Not Refer recommendation.
Study NCT00005613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Cyclophosphamide will be given at a dose of 1500 mg/m2/day IV over 1.0 hour on days -6, -5, -4, and -3.
Study NCT00005613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Etoposide will be given at a dose of 600 mg/m2/day over 3.0 hours on days -6, -5, and -4.
Study NCT00005613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCNU
Description: BCNU will be given at a dose of 150 mg/m2/day in 500 cc D5W over 3.0 hours on days -6, -5, and -4
Study NCT03253341 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smart Aging Program
Description: Comprehensive lifestyle and fitness program designed to improve the health of older adults. The Smart Aging Program represents a package consisting of a dedicated health coach, mobile monitoring, specialized curriculum, and exercise opportunities.
Study NCT03253341 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Materials
Description: Current standard of care. Includes education materials covering benefits of a healthy lifestyle.
Study NCT01900418 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Walk with Ease
Description: An evidence-based walking program